Values tool to help AML patients choose treatments

Who could benefit from this research

What this research studies

This grant supports Dr. Daniel Richardson as he becomes an independent cancer care researcher focused on AML patient care. The project will test a tool called PRIME that creates a personalized values report in real time to support shared decision-making between patients and clinicians. The aim is to see if PRIME is feasible for use in AML care and whether it helps patients and doctors discuss preferences and trade-offs more clearly. The work builds on prior AML research and uses a robust values-clarification method to align treatment choices with patient goals.

Why it matters

Where this research is happening

• Univ of North Carolina Chapel Hill
  Chapel Hill, United States Active

Researchers

• Principal investigator: Richardson, Daniel R — Univ of North Carolina Chapel Hill
• Study coordinator: Richardson, Daniel R

Related research

Other NIH-funded projects on the same topics.

• Creating a tool to help patients with acute myeloid leukemia make treatment decisions

  This study is creating a helpful tool called PRIME for people with acute myeloid leukemia (AML) to express what matters most to them in their treatment, so they can make better decisions with their doctors about their care.

  NIH research Univ of North Carolina Chapel Hill · Chapel Hill, United States · NIH-11112298

• Targeting the SCP4 pathway in acute myeloid leukemia (AML)

  Aims to uncover how the SCP4 signaling pathway drives AML and how it could be blocked to help patients.

  NIH research St. Jude Children's Research Hospital · Memphis, United States · NIH-11617813

• Interferon-γ plus donor immune cells to fight AML/MDS after partial donor transplant

  This project tests a therapy that adds a signaling protein, IFN-γ, with donor immune cells to help treat relapsed AML/MDS after a haploidentical stem cell transplant.

  NIH research University of Pittsburgh at Pittsburgh · Pittsburgh, United States · NIH-11453101

• Targeting the protein housekeeping system in adult leukemia

  Researchers are testing a new approach to treat acute myeloid leukemia by disrupting how AML cells manage their proteins, with the goal of helping patients live longer and healthier lives.

  NIH research University of California, San Diego · La Jolla, United States · NIH-11452453

• Understanding how epigenetic helper proteins drive AML and how to target them

  A scientist team is studying how accessory proteins in gene-regulating complexes affect acute myeloid leukemia and whether they can be targeted for safer, more precise therapies.

  NIH research University of Alabama at Birmingham · Birmingham, United States · NIH-11448341

• Targeting FLVCR1-enabled choline use in a aggressive AML subtype

  A new approach aims to block how a specific leukemia subtype (CG-AML) takes up choline to feed its growth, potentially slowing or stopping the disease.

  NIH research Seattle Children's Hospital · Seattle, United States · NIH-11427960

About this research

1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.